Two-year update of ZUMA-2 Cohort 3: Brexucabtagene autoleucel (Brexu-cel) in patients (pts) with relapsed/refractory mantle cell lymphoma (R/R MCL) who had not received prior Bruton tyrosine kinase inhibitor (BTKi) therapy
Phase 2 study demonstrates 91% response rate in BTKi-naive patients with relapsed mantle cell lymphoma, indicating a potential earlier treatment benefit.
Key Points
This research aims to evaluate the efficacy of brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma who are naive to Bruton tyrosine kinase inhibitors.
Phase 2 study design with 86 BTKi-naive patients enrolled.
Patients underwent leukapheresis, lymphodepleting chemotherapy, and infusion of brexu-cel.
Primary endpoint was objective response rate determined by independent radiology review.
The study reported a 91% objective response rate with a 79% complete response rate.
Median follow-up of 26.4 months revealed significant ongoing responses in various subgroups.
Safety profile showed a high incidence of Grade ≥3 adverse events, but late onset toxicities were rare.